Related Experiment Video

Updated: Sep 29, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

[Left ventricular hypertrophy in patients with chronic renal failure treated by hemodialysis]

Maria Wanic-Kossowska1, Piotr Lehmann, Stanisław Czekalski

  • 1Klinika Nefrologii AM w Poznaniu.

Polskie Archiwum Medycyny Wewnetrznej
|October 12, 2002
PubMed

Insights

Left ventricular hypertrophy (LVH) is prevalent in chronic renal failure (CRF) patients undergoing hemodialysis (HD). Elevated parathyroid hormone (PTH) and low body mass index (BMI) are key factors contributing to LVH development.

Area of Science:

  • Nephrology
  • Cardiology
  • Internal Medicine

Background:

  • Left ventricular hypertrophy (LVH) is a significant predictor of mortality in end-stage renal failure.
  • Chronic renal failure (CRF) patients on hemodialysis (HD) frequently develop LVH.

Purpose of the Study:

  • To investigate the prevalence of LVH and identify associated risk factors in CRF patients undergoing HD.
  • To analyze the relationship between echocardiographic findings and clinical/biochemical parameters.

Main Methods:

  • Echocardiography (ECHO) was used to assess LVH in 59 clinically stable CRF patients on HD.
  • Evaluated parameters included body mass index (BMI), serum creatinine, urea, albumin, hemoglobin, and parathyroid hormone (PTH).

Main Results:

  • LVH was common, with 46 patients showing concentric and 13 showing eccentric patterns.
  • Significant positive correlations were observed between serum PTH concentrations and left ventricular mass (LVM), interventricular septum (IVS), and posterior wall (PW) thickness.
  • A negative correlation was found between BMI and LVMI, indicating malnutrition as a factor.

Conclusions:

  • Hyperparathyroidism (elevated PTH) and malnutrition (low BMI) are crucial factors influencing LVH development in HD patients.
  • These findings highlight the importance of managing PTH levels and nutritional status to mitigate cardiac risk.

More Related Videos

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...